Whether in comedy or commerce, timing is everything, and Vivo Capital appears to have timed its recent fundraising just right. Founded in 1996 as BioAsia, Vivo Capital began as an anomaly in Silicon Valley, a life sciences venture firm investing Asian dollars into US-based biopharmaceutical and medical devices. A principle plank in the firm’s investing platform involved bringing a US-developed life sciences start-up mentality back to Asia, but the firm quickly identified the true opportunity – exporting US-made drugs and devices into China’s burgeoning health care system. (See Also see "Vivo Ventures’ Time Arrives As All Eyes Look To China" - In Vivo, 19 December, 2012..)
Fast forward nearly 20 years, and the former BioAsia – now Vivo Capital – has leveraged those Pan-Pacific connections to raise $750 million for its eighth fund, a partnership exactly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?